Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 1/20 | 0.50 |
| ▸ | ERN1 | O75460 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | AR | P10275 | 1/20 | 0.44 |
| ▸ | PELP1 | Q8IZL8 | 1/20 | 0.44 |
| ▸ | BACE1 | P56817 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.43 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.43 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.43 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3970653 | 1.00 | VCAM1 (0.50) | VCAM1ERN1ALDH1A1MAPTAR | |
| SCHEMBL191304 | 0.90 | VCAM1 (0.53) | VCAM1ERN1ALDH1A1MAPTBACE1 | |
| SCHEMBL191305 | 0.90 | VCAM1 (0.53) | VCAM1ERN1ALDH1A1MAPTBACE1 | |
| SCHEMBL11833572 | 0.86 | ALDH1A1 (0.54) | ALDH1A1MAPTPKMLMNAKMT2A | |
| SCHEMBL11833581 | 0.86 | ALDH1A1 (0.54) | ALDH1A1MAPTPKMLMNAKMT2A | |
| SCHEMBL7006049 | 0.85 | CASP6 (0.55) | ALDH1A1MAPTBACE1LMNA | |
| SCHEMBL7006042 | 0.85 | CASP6 (0.55) | ALDH1A1MAPTBACE1LMNA | |
| SCHEMBL13778767 | 0.85 | MAPT (0.48) | ERN1ALDH1A1MAPTBACE1AKR1C3 | |
| SCHEMBL7006045 | 0.85 | CASP6 (0.55) | ALDH1A1MAPTBACE1LMNA | |
| SCHEMBL3348706 | 0.82 | VCAM1 (0.53) | VCAM1ERN1ALDH1A1MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009047240-A1 | INDOLE DERIVATIVES USEFUL AS PPAR ACTIVATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-04-16 | — | — | WO | disclosed |
| WO-2009047240-A1 | INDOLE DERIVATIVES USEFUL AS PPAR ACTIVATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-04-16 | — | — | WO | disclosed |
| US-7511145-B2 | Bicyclic heteroaryl derivatives | GENELABS TECHNOLOGIES, INC. (US) | 2009-03-31 | — | — | US | disclosed |
| US-7511145-B2 | Bicyclic heteroaryl derivatives | GENELABS TECHNOLOGIES, INC. (US) | 2009-03-31 | — | — | US | disclosed |
| US-7511145-B2 | Bicyclic heteroaryl derivatives | GENELABS TECHNOLOGIES, INC. (US) | 2009-03-31 | — | — | US | disclosed |
| US-20090081165-A1 | BICYCLIC HETEROARYL DERIVATIVES | GENELABS TECHNOLOGIES, INC. | 2009-03-26 | — | — | US | disclosed |
| US-20090081165-A1 | BICYCLIC HETEROARYL DERIVATIVES | GENELABS TECHNOLOGIES, INC. | 2009-03-26 | — | — | US | disclosed |
| US-20090081165-A1 | BICYCLIC HETEROARYL DERIVATIVES | GENELABS TECHNOLOGIES, INC. | 2009-03-26 | — | — | US | disclosed |
| US-7115647-B2 | Method of inhibiting neoplastic cells with indole derivatives | OSI PHARMACEUTICALS, INC. (US) | 2006-10-03 | — | — | US | disclosed |
| EP-1651631-A1 | BICYCLIC IMIDAZOL DERIVATIVES AGAINST FLAVIVIRIDAE | GENELABS TECHNOLOGIES, INC. (US) | 2006-05-03 | — | — | EP | disclosed |
| US-20020143022-A1 | Method of inhibiting neoplastic cells with indole derivatives | OSI PHARMACEUTICALS, INC. | 2002-10-03 | — | — | US | disclosed |
| US-6410584-B1 | ANTICANCER AGENTS | CELL PATHWAYS, INC. | 2002-06-25 | — | — | US | disclosed |
| EP-0489547-B1 | A process for the preparation of a 3-alkylated indole, intermediates, and a process for the preparation of a derivative thereof | ZENECA LTD (GB) | 1998-07-29 | — | — | EP | disclosed |
| US-5334765-A | Intermediate for leukotriene antagonists | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1994-08-02 | — | — | US | disclosed |
| US-5286740-A | Leukotrine antagonists; antiinflammatory agnets, antiallergens, treating asthma | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1994-02-15 | — | — | US | disclosed |
| US-5280125-A | Chemical process for the preparation of 3-alkylated indole | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1994-01-18 | — | — | US | disclosed |
| EP-0489547-A1 | A process for the preparation of a 3-alkylated indole, intermediates, and a process for the preparation of a derivative thereof | ZENECA LIMITED (GB) | 1992-06-10 | — | — | EP | disclosed |
| CN-1015262-B | The method for preparing β-Nei Xiananleikangshengsu | BAYER AG (DE) | 1992-01-01 | — | — | CN | disclosed |
| US-4734407-A | ANIMAL GROWTH REGULATORS | BAYER AKTIENGESELLSCHAFT (DE) | 1988-03-29 | — | — | US | disclosed |
| CN-86101695-A | Prepare the method for β-Nei Xiananleikangshengsu and the application in medicine thereof | — | 1986-09-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143022-A1 | Method of inhibiting neoplastic cells with indole derivatives | IDO1, IDO2, INMT | VCAM1 2038/4885ERN1 2994/4885ALDH1A1 1463/4885 |
| US-20090081165-A1 | BICYCLIC HETEROARYL DERIVATIVES | HAVCR2, MAVS, ZC3HAV1 | VCAM1 3026/4885ERN1 969/4885ALDH1A1 2299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.